RightFit
RecruitingPhase 2

Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)

Investigating Enteroendocrine Dysfunction, Metabolism, and Response to Liraglutide in Patients With Maturity-onset Diabetes of the Young (MODY)

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
10 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests liraglutide, a medicine often used for type 2 diabetes, in people with maturity-onset diabetes of the young (MODY). It looks at how the drug affects the way the body uses food for energy and hormone levels, and whether it helps stomach and gut problems.

The reason for this research study is to better understand the use of liraglutide, a commonly prescribed Type 2 diabetes medication, in patients with a diagnosis of maturity-onset diabetes of the young (MODY). The investigators are interested in better understanding the way that this drug affects the metabolism and hormone levels of a person with MODY. Many people with MODY report having gastrointestinal (GI) issues such as an upset stomach. Investigators also are interested in finding out if this drug will help with GI issues. If liraglutide does help with this symptom of MODY, the investigators want to know why this happens. If this drug is effective for participants, the investigators will use participants cells to make human induced pluripotent stem cell (iPSC). This means that the investigators will use participant cells to create what are called stem cells, which are cells in the body that are able to be told what their job is. Investigators will use these cells to see what happens in gastrointestinal (GI) tract.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Have MODY confirmed by a genetic test.
  • Have an HbA1c above 6.5%. This blood test measures average blood sugar.

Who can't join

  • Have had a severe allergic reaction to GLP-1 medicines, the type of medicine liraglutide is, or already take one.
  • Take stimulant medicines or have had weight-loss surgery.
  • Have a personal or family history of cancer, especially medullary thyroid cancer, a type of thyroid cancer.
  • Have had pancreatitis (swelling of the pancreas), or have gene changes that raise the risk of it.
  • Have known, active kidney disease.
  • Have an HbA1c above 10.0%, or have had blood sugar below 50 mg/dL in the past 3 months.
  • Have had diabetic ketoacidosis (dangerous acid buildup from diabetes) in the past 3 months, or are pregnant now.
  • Have a BMI below 18.5, or, for children, below the 5th percentile. BMI is a measure of weight compared with height.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Diagnosis of MODY via genetic testing * HgbA1c \>6.5% Exclusion Criteria: * History of anaphylaxis to GLP-1 receptor agonists * Already taking GLP-1 receptor agonists * on medications within the stimulant class * have had bariatric surgery * personal or family history of cancer, especially medullary thyroid cancer * personal history of pancreatitis or pathogenic variants associated with increased risk of pancreatitis * known active kidney disease * severe hypoglycemia (glucose \< 50 mg/dL) within 3 months of study enrollment * HbA1c \> 10.0% * episode of diabetic ketoacidosis (DKA) in the past 3 months * are currently pregnant * BMI \< 18.5 kg/m2 and pediatric patients with BMI \< 5th percentile

Study sites (1)

OH